Regeneron Pharmaceuticals
The Regional Access Lead for Rare Diseases (Europe) at Regeneron is responsible for shaping and advancing market access and reimbursement strategies across European markets to ensure patient access to innovative rare disease therapies. The role works closely with global, regional, and local teams and external stakeholders to align policy and value propositions across the EU. It contributes to Regeneron’s mission of expanding access to life-changing treatments for patients across Europe.
Headquarters
Tarrytown, New York, United States
Company Size
10001+ employees
Founded
1988
Discover how Regeneron (NASDAQ: REGN) harmonizes biology and technology to create life-changing medicines. Join our team and explore clinical trials.
Quadrant Capital Group LLC Purchases 1,564 Shares of Regeneron Pharmaceuticals, Inc. $REGN
4 hours ago
In 2036, Investors Will Regret Not Loading Up on This Multibagger in the Making
6 hours ago
Will Positive Obesity Data and Dupixent Expansion Efforts Change Regeneron Pharmaceuticals' (REGN) Narrative?
1 day ago
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Regeneron Pharmaceuticals.
Regeneron Pharmaceuticals didn’t post a salary, so this is our estimate from similar listings.
Regeneron: Fairly Valued Now After A Stellar Upswing (NASDAQ:REGN)
1 day ago